Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $37.1 million.

  • 4D Molecular Therapeutics' Total Current Liabilities rose 2593.59% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 2593.59%. This contributed to the annual value of $29.1 million for FY2024, which is 5381.25% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Total Current Liabilities is $37.1 million, which was up 2593.59% from $34.7 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Total Current Liabilities ranged from a high of $37.1 million in Q3 2025 and a low of $9.9 million during Q2 2021
  • In the last 5 years, 4D Molecular Therapeutics' Total Current Liabilities had a median value of $16.3 million in 2021 and averaged $19.1 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 1311.44% in 2022, then skyrocketed by 7871.98% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Current Liabilities (Quarter) stood at $16.3 million in 2021, then fell by 3.72% to $15.7 million in 2022, then rose by 20.47% to $19.0 million in 2023, then surged by 53.81% to $29.1 million in 2024, then rose by 27.3% to $37.1 million in 2025.
  • Its last three reported values are $37.1 million in Q3 2025, $34.7 million for Q2 2025, and $26.9 million during Q1 2025.